Navigation Links
Campbell Alliance Launches Market Research and Analytics Group, Appoints Michael Turner as General Manager of Encuity Research
Date:3/21/2012

NEW YORK, March 21, 2012 /PRNewswire/ -- Campbell Alliance, an inVentiv Health company and the leading management consulting firm specializing in the pharmaceutical and biotech industry, today announced the launch of Encuity Research, the firm's market research and analytics subsidiary. Michael Turner, a six-year veteran with Campbell Alliance, will serve as General Manager of Encuity Research. The company will be based in Newtown, PA.

(Photo: http://photos.prnewswire.com/prnh/20120321/CL73567)

The launch of Encuity Research immediately follows the acquisition of SDI Health's promotional and medical audit businesses from IMS Health. The deal closed on March 20, 2012, and financial terms of the transaction were not disclosed.

According to Nader Naeymi-Rad, CEO of Campbell Alliance, "The audit businesses acquired from IMS will be combined with our existing market research and analytics service lines to create a very robust business that will drive accelerated growth for us in the market research segment. In addition, Encuity Research's services will provide Campbell Alliance and our parent company, inVentiv Health, with new insights for clients that will enhance our ability to deliver powerful solutions."

Encuity Research will provide a range of services to the pharmaceutical and biotech industry in five specific areas, including:

  • Custom quantitative research and analytics
  • Qualitative research
  • Key opinion leader identification and mapping
  • Message tracking including Rapid Recall(SM) message effectiveness studies

Syndicated audits including the Metropolitan Area Promotional Audit, which tracks promotional activity across 15 specialty therapeutic areas; VisionCare, offering fitting and dispensing trend data on the contact lens market in the U.S. and Canada; an
'/>"/>

SOURCE Campbell Alliance
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Campbell Alliance Launches New Practice Area Focused on Medical Affairs
2. Campbell Alliance Adds Industry Veterans Jon W. McGarity and David Lilley as Executive Vice Presidents
3. SENOMYX ANNOUNCES EXTENSION OF ITS COLLABORATION WITH CAMPBELL SOUP COMPANY
4. Campbell Alliance Brand Management Practice to Present at EyeForPharmas Oncology Summit USA and Oncology Market Access Europe Conference
5. Campbell Alliance Hires Joe Dillon, Expands Business Development Practice
6. Campbell Alliance Sales Practice to Present at CBIs Leadership Summit on Evolving the Pharma Sales Model
7. Nader Naeymi-Rad Appointed Chief Operating Officer at Campbell Alliance
8. Darius Naigamwalla Appointed Senior Vice President and Head of the Brand Management Practice at Campbell Alliance
9. Systems Alliance Launches Redesigned Website for The Living Legacy Foundation of Maryland
10. SiREM and Tersus Environmental Form Strategic Marketing Alliance
11. PAREXEL and ASAN Medical Center Establish Alliance to Accelerate Korea-based Drug Development and Commercialization Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 19, 2014 Bioject Medical Technologies ... manufacturer of needle-free injection technology, today announced that ... Therapeutics, Inc. (“ITI”) for ITI to use the ... LAMP™ vaccine platform. , In the agreement, ... license to the Biojector®-2000 that triggers based on ...
(Date:12/19/2014)... 2014 Naurex Inc., a biopharmaceutical company leveraging ... of the central nervous system, today announced that ... will present at the 33 rd annual J.P. ... at 3:00 p.m. PST on Tuesday, January 13, 2015, ... Francisco, Calif. About Naurex ...
(Date:12/19/2014)... 19, 2014 Decision Resources Group finds that ... a 12 percent compound annual growth rate through 2023. ... population and the increasing adoption of dental implants. Growing ... will also spur demand for dental biomaterials because they ... periodontal treatments. Other key findings from Decision ...
(Date:12/19/2014)... Arkansas (PRWEB) December 18, 2014 ... to locate its pilot production facility and future ... develop and produce innovative new materials that safely ... chosen not only because of its historic, strong ... leaders’ efforts to attract leading edge, technology-based companies ...
Breaking Biology Technology:Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 2Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 4
... WALTHAM, Mass. , May 24 Repligen ... of Orphan Products Development of the Food and Drug Administration ... histone deacetylase 3 (HDAC-3) inhibitor for the treatment of Friedreich,s ... of marketing exclusivity in the United States if ...
... 24 MO BIO Laboratories, Inc., the leader ... the launch of a groundbreaking new product, PowerLyzer™ 24 ... homogenization and lysis of any biological sample.  The PowerLyzer™ ... analysis faster, minimize cross-contamination, and maintain sample integrity. ...
... CLEVELAND, Ohio , May 24, 2010 Simbionix ... medical professionals and the healthcare industry, is launching,two new hands-on training systems- ... revealed for the first time at,the AUA annual meeting in San ... , ...
Cached Biology Technology:Repligen Receives Orphan Drug Designation from the FDA for RG2833 for Friedreich's Ataxia 2Repligen Receives Orphan Drug Designation from the FDA for RG2833 for Friedreich's Ataxia 3Repligen Receives Orphan Drug Designation from the FDA for RG2833 for Friedreich's Ataxia 4MO BIO Laboratories, Inc. Launches PowerLyzer(TM) 24 Bench Top Bead-Based Homogenizer 2Simbionix to Reveal Two new Products at the Upcoming American Urology Association (AUA) Annual Meeting 2Simbionix to Reveal Two new Products at the Upcoming American Urology Association (AUA) Annual Meeting 3
(Date:12/19/2014)... LAS VEGAS , Dec. 18, 2014   ... platform built for the post-password and Internet of Things ... additional seed funding. The venture round was led by ... Pantera Capital, Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey ... the new funding to expand its team and bring ...
(Date:12/17/2014)... RALEIGH, N.C. , Dec. 16, 2014 ... has licensed its PerformTek biometric technology to industry leaders ... their highly accurate, clinically validated, biometric wearable products. These ... January 6-9 in Las Vegas . ... the technology is accurate, flexible and robust – with ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ...  report to their offering. One ... in technology. With continuous advances in technology, it ... latest standard that meets the needs and expectations ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... for the first time that coenzyme Q10 offsets the cellular ... drugs - an increased risk of adult-onset diabetes. Statins ... world, able to reduce LDL, or "bad" cholesterol levels, and ... their role in raising the risk of diabetes has only ...
... 10, 2013  Medbox, Inc. (OTC Markets: MDBX) ( www.medboxinc.com ... become a fully reporting public company with the Securities ... many highlights of the filing is a licensing agreement ... PVM International, Inc., has towards the company,s shareholders. The ...
... 2013, New York, NY A dozen Ludwig scientists ... basic and clinical cancer research at this week,s American ... in immunotherapy and epigenetics led the program with important ... "With new immunotherapy agents available to help ...
Cached Biology News:Co-Q10 deficiency may relate to concern with statin drugs, higher risk of diabetes 2Medbox Files Form 10 with SEC 2Ludwig advancements in immunotherapy and epigenetics top scientific program at AACR 2